Načítá se...
Severe Delayed-Onset Neutropenia Induced by Ocrelizumab
BACKGROUND: Ocrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS). The adverse event profile is still being determined through postmarketing surveillance and case reports. OBJECTIVE: To report a case of sev...
Uloženo v:
| Vydáno v: | Neurohospitalist |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8022193/ https://ncbi.nlm.nih.gov/pubmed/33868559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1941874420936438 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|